Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery
View Patent ↗A method for delivering a therapeutic agent to a subject from a transdermal delivery system is described, where the therapeutic agent (i) has a half-life in the blood when delivered orally of greater than about 48 hours and (ii) is for the treatment of a chronic condition. The transdermal delivery system achieves transdermal delivery of the therapeutic agent at steady state that is bioequivalent to administration of the therapeutic agent orally, wherein bioequivalency is established by (a) a 90% confidence interval of the relative mean Cmax and AUC of the therapeutic agent administered from the transdermal delivery system and via oral delivery between 0.70 and 1.43 or between 0.80 and 1.25, or (b) a 90% confidence interval of the ratios for AUC and Cmax of the therapeutic agent administered from the transdermal delivery system and via oral delivery between 0.70 and 1.43 or between 0.80 and 1.25.
1. A method for delivering donepezil base to a subject, comprising: providing a transdermal delivery system comprising a drug reservoir comprising a donepezil salt and an alkaline salt, applying the transdermal delivery system to the skin of a subject,
generating, after said applying, donepezil base in situ in the drug reservoir by reaction between the donepezil salt and the alkaline salt, and
delivering the donepezil base transdermally to the subject.
2. The method of claim 1 , wherein the applying comprises applying once weekly.
3. The method of claim 1 , wherein the transdermal delivery system comprises an amount of the donepezil salt sufficient to deliver to the skin between 1-25 mg of donepezil base in 24 hours.
4. The method of claim 1 , wherein the transdermal delivery system comprises a drug reservoir and a contact adhesive, wherein the drug reservoir, the contact adhesive, or both comprise one of (i) sorbitan monolaurate, (ii) triethyl citrate, and (iii) lauryl lactate.
5. The method claim 1 , wherein the transdermal delivery system comprises a drug reservoir comprising two of (i) lauryl lactate, (ii) triethyl citrate, and (iii) glycerol.
6. The method of claim 5 , wherein the drug reservoir comprises donepezil hydrochloride and sodium bicarbonate.
7. The method of claim 6 , wherein the drug reservoir additionally comprises one or both of sorbitan monolaurate and lauryl lactate.
8. A method for administering donepezil base to a subject, comprising:
applying to the skin of a subject a transdermal delivery system comprising a drug reservoir comprising (i) donepezil hydrochloride, and (ii) sodium bicarbonate, and (iii) a solvent composition comprising glycerol, triethyl citrate, lauryl lactate and sorbitan monolaurate,
generating, after said applying, donepezil base in situ in the drug reservoir by reaction between the donepezil HCl and the sodium bicarbonate; and
administering transdermally the donepezil base to the subject.
9. The method of claim 8 , wherein the drug reservoir of the transdermal delivery system further comprises between about 25-65 wt % acrylate co-polymer.
10. The method of claim 8 , wherein the drug reservoir of the transdermal delivery system comprises donepezil base generated in situ by reaction of between about 10-30 wt % donepezil hydrochloride and between about 0.5-10 wt % sodium bicarbonate.
11. The method of claim 10 , wherein the drug reservoir of the transdermal delivery system comprises between about 5-15 wt % triethyl citrate.
12. The method of claim 11 , wherein the drug reservoir of the transdermal delivery system comprises between about 1-10 wt % lauryl lactate.
13. The method of claim 12 , wherein the transdermal delivery system further comprises a skin contact adhesive layer that comprises triethyl citrate, lauryl lactate and sorbitan monolaurate.
14. The method of claim 11 , wherein the drug reservoir of the transdermal delivery system comprises an amount of donepezil hydrochloride sufficient to deliver a dose of donepezil base between 1-25 mg every 24 hours for at least about one week.
15. The method of claim 13 , wherein the drug reservoir of the transdermal delivery system comprises between about 2-20 wt % glycerol.
16. The method of claim 1 , wherein the drug reservoir comprises between about 10-30 wt % donepezil salt and between about 0.5-10 wt % alkaline salt.
17. The method of claim 1 , wherein the donepezil salt is donepezil hydrochloride and the alkaline salt is sodium bicarbonate.
18. The method of claim 17 , wherein the drug reservoir comprises between about 10-30 wt % donepezil HCl and between about 0.5-10 wt % sodium bicarbonate.